Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Hydrocodone Restrictions to Take Effect

By Drug Discovery Trends Editor | August 21, 2014

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.

 
The new rules mean that drugs like Vicodin, Lortab and their generic equivalents will be subject to the same prescribing rules as painkillers like codeine and oxycodone. Patients will be limited to one 90-day supply of medication and will have to see a health care professional to get a refill. In many states, only doctors will be able to prescribe the medications, not nurses or physician assistants.
 
“Today’s action recognizes that these products are some of the most addictive and potentially dangerous prescription medications available,” said DEA chief Michele Leonhart, in a statement.
 
The move, announced in a federal notice, comes more than a decade after the Drug Enforcement Administration first recommended reclassifying hydrocodone due to its risks for abuse and addiction. For years, physician groups and the Food and Drug Administration opposed the move, saying it would burden health care providers and patients while driving up costs.
 
But last year the FDA changed its position, citing the national epidemic of overdoses and deaths tied to prescription painkillers known as opioids.
 
Deaths linked to the drugs more than tripled between 1999 and 2010, during which sales of opioids increased four-fold.
 
Anti-addiction groups praised the restrictions, but criticized the FDA for taking nearly a decade to embrace the changes.
 
“Had FDA responded in a timely and appropriate manner to DEA’s urgent request, thousands of overdose deaths and tens of thousands of cases of opioid addiction might have been prevented,” said Physicians for Responsible Opioid Prescribing, an advocacy group which has been critical of the government’s approach to curbing abuse.
 
The new restrictions will go into effect in 45 days, according to a federal listing scheduled for publication Friday.
 
For decades, hydrocodone has been easier to prescribe than other opioids, in part because it was only sold in combination pills and formulas with other non-addictive ingredients like aspirin and acetaminophen.
 
The Controlled Substances Act, passed in 1970, put hydrocodone combination pills in the Schedule III class, which is subject to fewer controls than Schedule II drugs like morphine and methadone. Under Schedule III classification, a prescription for Vicodin could be refilled five times before the patient had to see a physician again.
 
That ease of access made it many health care professionals’ top choice for treating chronic pain, including everything from back pain to arthritis to toothaches.
 
In 2012, U.S. doctors wrote more than 125 million prescriptions for hydrocodone-containing medications, making it the most prescribed drug in the country, according to figures from IMS Health.
 
News of the rescheduling was applauded by lawmakers from states that have been plagued by opioid abuse, including those who have been pushing regulators to make the change.
 
“Although there is much more that must be done to curb prescription drug abuse, I am confident that rescheduling hydrocodone will undoubtedly begin saving hundreds of thousands of lives immediately,” said Senator Joe Manchin of West Virginia, in a statement.
 
Date: August 21, 2014
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE